drugset / Trial / NCT00151242

Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00151242

Phase 2/3 Completed 920 enrolled University of Ulm
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is a study on all-trans retinoic acid in combination with induction and consolidation therapy as well as pegfilgrastim after consolidation therapy in younger patients with newly diagnosed acute myeloid leukemia (AML).

Timeline

Start
2004-07
Primary completion
2011-08
Completion
2013-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tretinoin Small molecule 15 mg/m2 Oral
Background Cytarabine Small molecule 3 g Intravenous
Background Etoposide Small molecule 100 mg/m2 Intravenous
Background Idarubicin Small molecule 12 mg/m2 Intravenous
Background Pegfilgrastim Protein / enzyme biologic 6 mg Subcutaneous